Sanoculis

SanoculisSanoculis
Sanoculis

Sanoculis

Sanoculis develops MIMS®, a minimally invasive surgical device for glaucoma treatment, creating a drainage channel without implants or stitches.

DR 112012Active10Tel Aviv, Israel
Rate

About

Sanoculis is a medical device startup focused on developing innovative solutions for glaucoma treatment. Their flagship product, MIMS® (Minimally Invasive Micro Sclerostomy), is a surgical device designed to create a drainage channel to reduce intraocular pressure (IOP) in glaucoma patients. The MIMS® procedure aims for a long-lasting, safe, and controlled fluid flow without the need for stitches, eye-patches, implants, or stents, thereby reducing post-surgical complications and care costs.
Frequently asked

What does Sanoculis do?

Sanoculis is a medical device startup focused on developing innovative solutions for glaucoma treatment. Their flagship product, MIMS® (Minimally Invasive Micro Sclerostomy), is a surgical device designed to create a drainage channel to reduce intraocular pressure (IOP) in glaucoma patients. The MIMS® procedure aims for a long-lasting, safe, and controlled fluid flow without the need for stitches, eye-patches, implants, or stents, thereby reducing post-surgical complications and care costs.

What is Sanoculis's revenue?

StartupHub estimates Sanoculis's annual revenue at $1.8M (range $1.0M to $3.4M, 67% confidence), based on comparable companies in the sector.

Where is Sanoculis headquartered?

Sanoculis is headquartered in Tel Aviv, Israel.

When was Sanoculis founded?

Sanoculis was founded in 2012.

What industry does Sanoculis operate in?

Sanoculis operates in Healthcare, MedTech, Ophthalmology, Medical Device, Glaucoma Treatment, Minimally Invasive Surgery.

How many employees does Sanoculis have?

Sanoculis has approximately 10 people on record.

HEADCOUNT
10
DOMAIN RATING
11
Comments

No comments yet. Be the first to share your take.